This favorable outcome may result from the synergistic mechanisms of action: bendamustine induces DNA damage and enhances CD20 antigen expression, facilitating the activity of anti-CD20 antibodies; obinutuzumab, in turn, mediates effective clearance of residual leukemia cells via ADCC and complement-dependent cytotoxicity (CDC). The gene discussed is MS4A1; the disease is leukemia.